Full Press Release Details
CAMBRIDGE, Mass., Oct. 14, 2016 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that members of its scientific team will present new data at the European Society of Gene & Cell Therapy Congress (ESGCT) in Florence, Italy from October 18-21, 2016. Abstracts will be available online at esgct.eu on October 17, 2016.
“The data being presented at ESGCT show Intellia’s continued progress with its CRISPR/Cas9 platform,” said John Leonard, M.D., chief medical officer, Intellia Therapeutics. “These findings are important as we learn more about CRISPR/Cas9 and move toward clinical studies in patients.”
The following posters have been scheduled for presentation:
| Number | Poster Title | Presenter | Time |
| #283 | Efficient assessment of CRISPR/Cas9 off-target activity using a background double-strand break model | Reynald Lescarbeau, Ph.D. Computational Scientist, Bioinformatics | October 19, 2016 18:30 - 20:30 pm 12:30 - 2:30 pm ET |
| #280 | Robust in vivo gene editing in mouse hepatocytes with systemic lipid nanoparticle delivery of CRISPR/Cas9 components | David Morrissey, Ph.D. Chief Technology Officer | October 20, 2016 18:30 - 20:30 pm 12:30 - 2:30 pm ET |
| #320 | DNA repair events after cleavage by CRISPR/Cas9 are not random | Walter Strapps, Ph.D. Senior Director, Biology | October 20, 2016 18:30 - 20:30 pm 12:30 - 2:30 pm ET |
| #310 | Translating CRISPR/Cas9 genome editing into therapeutics | Tom Barnes, Ph.D. Chief Scientific Officer | October 20, 2016 18:30 - 20:30 pm 12:30 - 2:30 pm ET |
About Intellia Therapeutics
Contact Data
Jennifer Mound Smoter
Chief External Affairs & Communications Officer
Contact
With a Reader Account, it's easy to send email directly to the contact for this release. Sign up today for your free Reader Account!
Already have an account? Log in here.